The supplementation of GlcNAc to MS mouse models diminishes TLR4 and TLR2 signaling in B cells while also reducing pro-inflammatory T-cell-driven demyelination, and it could thus be a promising and inexpensive treatment for MS [236]. The gene discussed is TLR2; the disease is myeloid sarcoma.